PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study

Tychyj-Pinel, Christelle; Ricard, Fabien; Fulham, Michael; Fournier, Michel; Meignan, Michel; Lamy, Thierry; Véra, Pierre; Salles, Gilles; Trotman, Judith

doi:10.1007/s00259-013-2441-8

Cited by 40 publications

(16 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[34][35][36][37][38][39][40][41] There was, however, no association between baseline SUV max and either PFS or response, in agreement with the results of another recent study in FL. [31] SUV is derived from a single measurement in Table 3. Impact on PFS of percentage change in SUV, MTV, and TLG between baseline and EOI treatment using optimal cutoff values.…”

Section: Discussionmentioning

confidence: 99%

FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study

Kostakoğlu

Goy

Martinelli

et al. 2016

Leukemia & Lymphoma

View full text Add to dashboard Cite

An exploratory analysis of 75 follicular lymphoma patients treated with obinutuzumab or rituximab induction therapy (IT) for 4 weeks in the phase II GAUSS study aimed to determine whether positron emission tomography (PET) results could predict progression-free survival (PFS) and tumor response. The proportion of patients with a PFS event (progression or death) was higher in those who were PET-positive after IT (assessed using Deauville five-point scale criteria; 35/52, 67%) than PET-negative (5/20, 25%); the hazard ratio for progression or death was 0.25 (95%CI: 0.01-0.64; p = 0.0018). A significant association was also found when PET results were assessed using International Harmonization Project and European Organisation for Research and Treatment of Cancer criteria. Change between baseline and end of IT in values of standardized uptake value and other PET parameters were associated with PFS and response. Validation of these results in prospective studies of larger cohorts is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study

Kostakoğlu

Goy

Martinelli

et al. 2016

Leukemia & Lymphoma

View full text Add to dashboard Cite

show abstract

“…An extensive number of studies have shown that FDG-PET performed post-treatment is highly predictive of PFS and OS with and without residual masses on CT. The vast number of studies in aggressive NHL has been summarized in a systematic review [63], while the data on indolent NHL are based on fewer studies [64][65][66]. Based on these findings, the International Harmonization Project developed new recommendations for response criteria for aggressive malignant lymphomas, incorporating FDG-PET into the definitions of end-of-treatment response in FDG-avid lymphomas [67,68].…”

Section: Pet/ct For Post-therapy Response Evaluation Of Lymphomasmentioning

confidence: 99%

Imaging of Non-Hodgkin Lymphomas: Diagnosis and Response-Adapted Strategies

El‐Galaly

Hutchings

2015

Cancer Treatment and Research

View full text Add to dashboard Cite

Optimal lymphoma management requires accurate pretreatment staging and reliable assessment of response, both during and after therapy. Positron emission tomography with computerized tomography (PET/CT) combines functional and anatomical imaging and provides the most sensitive and accurate methods for lymphoma imaging. New guidelines for lymphoma imaging and recently revised criteria for lymphoma staging and response assessment recommend PET/CT staging, treatment monitoring, and response evaluation in all FDG-avid lymphomas, while CT remains the method of choice for non-FDG-avid histologies. Since interim PET imaging has high prognostic value in lymphoma, a number of trials investigate PET-based, response-adapted therapy for non-Hodgkin lymphomas (NHL). PET response is the main determinant of response according to the new response criteria, but PET/CT has little or no role in routine surveillance imaging, the value which is itself questionable. This review presents from a clinical point of view the evidence for the use of imaging and primarily PET/CT in NHL before, during, and after therapy. The reader is given an overview of the current PET-based interventional NHL trials and an insight into possible future developments in the field, including new PET tracers.

show abstract

“…These studies suggested that using the hepatic FDG activity, as a reference cut-off for PET positivity in HL, is better than using the mediastinal blood pool [19]. Recently, TychyjPinel et al [20] has shown that PET positivity determined using the IHP criteria failed to predict progression. However, PET positivity determined using the Deauville 5-point scale (with a cut-off of C4) did predict progression, with 3.5-year PET-positive and PET-negative PFS of 25.0 and 61.4 %, respectively.…”

Section: Discussionmentioning

confidence: 97%

The prognostic value of mid- and post-treatment [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma

et al. 2014

View full text Add to dashboard Cite

show abstract

PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study

Cited by 40 publications

References 31 publications

FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study

FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study

Imaging of Non-Hodgkin Lymphomas: Diagnosis and Response-Adapted Strategies

The prognostic value of mid- and post-treatment [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma

Contact Info

Product

Resources

About